Advertisement

Supportive Care in Cancer

, Volume 24, Issue 5, pp 2139–2146 | Cite as

Aromatase inhibitor induced musculoskeletal syndrome: a significant problem with limited treatment options

  • Janine M. LombardEmail author
  • Nicholas Zdenkowski
  • Kathy Wells
  • Corinna Beckmore
  • Linda Reaby
  • John F. Forbes
  • Jacquie Chirgwin
Original Article

Abstract

Background

Aromatase inhibitor induced musculoskeletal syndrome is experienced by approximately half of women taking aromatase inhibitors, impairing quality of life and leading some to discontinue treatment. Evidence for effective treatments is lacking. We aimed to understand the manifestations and impact of this syndrome in the Australian breast cancer community, and strategies used for its management.

Methods

A survey invitation was sent to 2390 members of the Breast Cancer Network Australia Review and Survey Group in April 2014. The online questionnaire included 45 questions covering demographics, aromatase inhibitor use, clinical manifestations and risk factors for the aromatase inhibitor musculoskeletal syndrome, reasons for treatment discontinuation and efficacy of interventions used.

Results

Aromatase inhibitor induced musculoskeletal syndrome was reported by 302 (82 %) of 370 respondents. Twenty-seven percent had discontinued treatment for any reason and of these, 68 % discontinued because of the musculoskeletal syndrome. Eighty-one percent had used at least one intervention from the following three categories to manage the syndrome: doctor prescribed medications, over-the-counter/complementary medicines or alternative/non-drug therapies. Anti-inflammatories, paracetamol (acetaminophen) and yoga were most successful in relieving symptoms in each of the respective categories. Almost a third of respondents reported that one or more interventions helped prevent aromatase inhibitor discontinuation. However, approximately 20 % of respondents found no intervention effective in any category.

Conclusion

We conclude that aromatase inhibitor induced musculoskeletal syndrome is a significant issue for Australian women and is an important reason for treatment discontinuation. Women use a variety of interventions to manage this syndrome; however, their efficacy appears limited.

Keywords

Early breast cancer Aromatase inhibitor Arthralgia Arthritis Myalgia Interventions 

Notes

Acknowledgments

We thank the study participants, the Breast Cancer Institute of Australia (BCIA) as the fundraising arm of the Australia and New Zealand Breast Cancer Trials Group (ANZBCTG), the ANZBCTG Trial Coordination Department and the Breast Cancer Network Australia for administering the survey.

Contribution

All authors have contributed to the planning and conduct of the study and the analysis of the data. All authors have approved the final submitted manuscript.

Compliance with ethical standards

Conflict of interest

No authors had any conflict of interest to declare.

Funding

This study was funded by the Australia and New Zealand Breast Cancer Trials Group (ANZBCTG).

References

  1. 1.
    Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret J-M, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25(5):486–492. doi: 10.1200/jco.2006.08.8617 CrossRefPubMedGoogle Scholar
  2. 2.
    Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJH, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369(9561):559–570CrossRefPubMedGoogle Scholar
  3. 3.
    The Arimidex TAoiCATG (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9(1):45–53. doi: 10.1016/S1470-2045(07)70385-6 CrossRefGoogle Scholar
  4. 4.
    Lintermans A, Van Calster B, Van Hoydonck M, Pans S, Verhaeghe J, Westhovens R, Henry NL, Wildiers H, Paridaens R, Dieudonné AS, Leunen K, Morales L, Verschueren K, Timmerman D, De Smet L, Vergote I, Christiaens MR, Neven P (2011) Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis. Ann Oncol 22(8):1763–1769. doi: 10.1093/annonc/mdq699 CrossRefPubMedGoogle Scholar
  5. 5.
    Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N, Mansel RE, von Minckwitz G, Bonanni B, Palva T, Howell A (2014) Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 383(9922):1041–1048. doi: 10.1016/s0140-6736(13)62292-8 CrossRefPubMedGoogle Scholar
  6. 6.
    Briot K, Tubiana-Hulin M, Bastit L, Kloos I, Roux C (2010) Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat 120(1):127–134. doi: 10.1007/s10549-009-0692-7 CrossRefPubMedGoogle Scholar
  7. 7.
    Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA, Stearns V, Hayes DF, Storniolo AM (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 30(9):936–942. doi: 10.1200/jco.2011.38.0261 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Porter D (2013) New Zealand survey of aromatase inhibitor toxicityGoogle Scholar
  9. 9.
    Presant CA, Bosserman L, Young T, Vakil M, Horns R, Upadhyaya G, Ebrahimi B, Yeon C, Howard F (2007) Aromatase inhibitor–associated arthralgia and/or bone pain: frequency and characterization in non–clinical trial patients. Clin Breast Cancer 7(10):775–778. doi: 10.3816/CBC.2007.n.038 CrossRefPubMedGoogle Scholar
  10. 10.
    Zivian MT, Salgado B (2008) Side effects revisitied: Women’s experiences with aromatase inhibitors. Breast Cancer Action, San FranciscoGoogle Scholar
  11. 11.
    Lintermans A, Van Asten K, Wildiers H, Laenen A, Paridaens R, Weltens C, Verhaeghe J, Vanderschueren D, Smeets A, Van Limbergen E, Leunen K, Christiaens MR, Neven P (2014) A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI. Breast Cancer Res Treat 146(1):109–116. doi: 10.1007/s10549-014-2986-7 CrossRefPubMedGoogle Scholar
  12. 12.
    Barron TI, Cahir C, Sharp L, Bennett K (2013) A nested case–control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage I-III breast cancer. Br J Cancer 109(6):1513–1521. doi: 10.1038/bjc.2013.518 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Chirgwin J, Giobbie-Hurder A. Treatment adherence in the BIG 1-98 trial of tamoxifen, letrozole alone and in sequenceGoogle Scholar
  14. 14.
    Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, Kwan M, Gomez SL, Neugut AI (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126(2):529–537. doi: 10.1007/s10549-010-1132-4 CrossRefPubMedGoogle Scholar
  15. 15.
    Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C (2013) Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 108(7):1515–1524. doi: 10.1038/bjc.2013.116 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, Fahey TP (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99(11):1763–1768. doi: 10.1038/sj.bjc.6604758 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    McCowan C, Wang S, Thompson AM, Makubate B, Petrie DJ (2013) The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study. Br J Cancer 109(5):1172–1180. doi: 10.1038/bjc.2013.464 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Stearns V, Chapman JA, Ma CX, Ellis MJ, Ingle JN, Pritchard KI, Budd GT, Rabaglio M, Sledge GW, Le Maitre A, Kundapur J, Liedke PE, Shepherd LE, Goss PE (2015) Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial. J Clin Oncol 33(3):265–271. doi: 10.1200/jco.2014.57.6926 CrossRefPubMedGoogle Scholar
  19. 19.
    Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ (2012) Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2–3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. Lancet Oncol 13(4):420–432. doi: 10.1016/s1470-2045(11)70328-x CrossRefPubMedGoogle Scholar
  20. 20.
    Cuzick J, Sestak I, Cella D, Fallowfield L (2008) Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 9(12):1143–1148. doi: 10.1016/s1470-2045(08)70259-6 CrossRefPubMedGoogle Scholar
  21. 21.
    Fontein DB, Seynaeve C, Hadji P, Hille ET, van de Water W, Putter H, Kranenbarg EM, Hasenburg A, Paridaens RJ, Vannetzel JM, Markopoulos C, Hozumi Y, Bartlett JM, Jones SE, Rea DW, Nortier JW, van de Velde CJ (2013) Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis. J Clin Oncol 31(18):2257–2264. doi: 10.1200/jco.2012.45.3068 CrossRefPubMedGoogle Scholar
  22. 22.
    Huober J, Cole BF, Rabaglio M, Giobbie-Hurder A, Wu J, Ejlertsen B, Bonnefoi H, Forbes JF, Neven P, Lang I, Smith I, Wardley A, Price KN, Goldhirsch A, Coates AS, Colleoni M, Gelber RD, Thurlimann B (2014) Symptoms of endocrine treatment and outcome in the BIG 1-98 study. Breast Cancer Res Treat 143(1):159–169. doi: 10.1007/s10549-013-2792-7 CrossRefPubMedGoogle Scholar
  23. 23.
    Crew KD, Capodice JL, Greenlee H, Brafman L, Fuentes D, Awad D, Yann Tsai W, Hershman DL (2010) Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor–associated joint symptoms in women with early-stage breast cancer. J Clin Oncol 28(7):1154–1160. doi: 10.1200/jco.2009.23.4708 CrossRefPubMedGoogle Scholar
  24. 24.
    Mao JJ, Xie SX, Farrar JT, Stricker CT, Bowman MA, Bruner D, DeMichele A (2014) A randomised trial of electro-acupuncture for arthralgia related to aromatase inhibitor use. Eur J Cancer 50(2):267–276. doi: 10.1016/j.ejca.2013.09.022 CrossRefPubMedGoogle Scholar
  25. 25.
    Irwin ML, Cartmel B, Gross CP, Ercolano E, Li F, Yao X, Fiellin M, Capozza S, Rothbard M, Zhou Y, Harrigan M, Sanft T, Schmitz K, Neogi T, Hershman D, Ligibel J (2015) Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol 33(10):1104–1114. doi: 10.1200/jco.2014.57.1547 CrossRefPubMedGoogle Scholar
  26. 26.
    Rastelli AL, Taylor ME, Villareal R, Jamalabadi-Majidi S, Gao F, Ellis MJ (2009) A double blind randomised placebo controlled trial of high dose vitamin D therapy on musculoskeletal pain and bone mineral density in anastrazole treated breast cancer patients with marginal vitamin D status. Paper presented at the San Antonio Breast Cancer Symposium, San AntonioGoogle Scholar
  27. 27.
    Greenlee H, Crew K, Shao T, Kranwinkel G, Kalinsky K, Maurer M, Brafman L, Insel B, Tsai W, Hershman D (2013) Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer. Support Care Cancer 21(4):1077–1087. doi: 10.1007/s00520-012-1628-z CrossRefPubMedGoogle Scholar
  28. 28.
    Kubo M, Onishi H, Kuroki S, Okido M, Shimada K, Yokohata K, Umeda S, Ogawa T, Tanaka M, Katano M (2012) Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer. Anticancer Res 32(6):2331–2336PubMedGoogle Scholar
  29. 29.
    Henry NL, Banerjee M, Wicha M, Van Poznak C, Smerage JB, Schott AF, Griggs JJ, Hayes DF (2011) Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms. Cancer 117(24):5469–5475. doi: 10.1002/cncr.26230 CrossRefPubMedGoogle Scholar
  30. 30.
    AIHW (2014) Cancer in Australia: an overview, 2014. vol Cancer series no. 90. Australian Institute of Health and Welfare & Australasian Association of Cancer Registries, CanberraGoogle Scholar
  31. 31.
    Division PB (2011) Australian Statistics on Medicines. Commonwealth of Australia. http://www.pbs.gov.au/info/statistics/asm/asm-2011. Accessed 7 Jan 2015
  32. 32.
    Fontaine C, Meulemans A, Huizing M, Collen C, Kaufman L, De Mey J, Bourgain C, Verfaillie G, Lamote J, Sacre R, Schallier D, Neyns B, Vermorken J, De Grève J (2008) Tolerance of adjuvant letrozole outside of clinical trials. Breast (Edinburgh, Scotland) 17(4):376–381CrossRefGoogle Scholar
  33. 33.
    Henry N, Giles J, Ang D, Mohan M, Dadabhoy D, Robarge J, Hayden J, Lemler S, Shahverdi K, Powers P, Li L, Flockhart D, Stearns V, Hayes D, Storniolo AM, Clauw D (2008) Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 111(2):365–372. doi: 10.1007/s10549-007-9774-6 CrossRefPubMedGoogle Scholar
  34. 34.
    Kidwell KM, Harte SE, Hayes DF, Storniolo AM, Carpenter J, Flockhart DA, Stearns V, Clauw DJ, Williams DA, Henry NL (2014) Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy. Cancer 120(16):2403–2411. doi: 10.1002/cncr.28756 CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Sestak I, Cuzick J, Sapunar F, Eastell R, Forbes JF, Bianco AR, Buzdar AU (2008) Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol 9(9):866–872. doi: 10.1016/s1470-2045(08)70182-7 CrossRefPubMedGoogle Scholar
  36. 36.
    Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25(25):3877–3883. doi: 10.1200/jco.2007.10.7573 CrossRefPubMedGoogle Scholar
  37. 37.
    Hashem MG, Cleary K, Fishman D, Nichols L, Khalid M (2013) Effect of concurrent prescription antiarthralgia pharmacotherapy on persistence to aromatase inhibitors in treatment-naive postmenopausal females. Ann Pharmacother 47(1):29–34. doi: 10.1345/aph.1R369 CrossRefPubMedGoogle Scholar
  38. 38.
    Magliano M (2010) Menopausal arthralgia: fact or fiction. Maturitas 67(1):29–33. doi: 10.1016/j.maturitas.2010.04.009 CrossRefPubMedGoogle Scholar
  39. 39.
    Tan AL, Emery P (2008) Role of oestrogen in the development of joint symptoms? Lancet Oncol 9(9):817–818. doi: 10.1016/s1470-2045(08)70217-1 CrossRefPubMedGoogle Scholar
  40. 40.
    Richette P, Corvol M, Bardin T (2003) Estrogens, cartilage, and osteoarthritis. Joint Bone Spine 70(4):257–262. doi: 10.1016/s1297-319x(03)00067-8 CrossRefPubMedGoogle Scholar
  41. 41.
    Felson DT, Cummings SR (2005) Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheumatism 52(9):2594–2598. doi: 10.1002/art.21364 CrossRefPubMedGoogle Scholar
  42. 42.
    Henry NL, Pchejetski D, A’Hern R, Nguyen AT, Charles P, Waxman J, Li L, Storniolo AM, Hayes DF, Flockhart DA, Stearns V, Stebbing J (2010) Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case–control study. Br J Cancer 103(3):291–296. doi: 10.1038/sj.bjc.6605768 CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Lintermans A, Vanderschueren D, Verhaeghe J, Van Asten K, Jans I, Van Herck E, Laenen A, Paridaens R, Billen J, Pauwels S, Vermeersch P, Wildiers H, Christiaens MR, Neven P (2014) Arthralgia induced by endocrine treatment for breast cancer: a prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens. Eur J Cancer 50(17):2925–2931. doi: 10.1016/j.ejca.2014.08.012 CrossRefPubMedGoogle Scholar
  44. 44.
    Rastelli AL, Taylor ME, Gao F, Armamento-Villareal R, Jamalabadi-Majidi S, Napoli N, Ellis MJ (2011) Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial. Breast Cancer Res Treat 129(1):107–116. doi: 10.1007/s10549-011-1644-6 CrossRefPubMedGoogle Scholar
  45. 45.
    Khan QJ, Reddy PS, Kimler BF, Sharma P, Baxa SE, O’Dea AP, Klemp JR, Fabian CJ (2010) Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 119(1):111–118. doi: 10.1007/s10549-009-0495-x CrossRefPubMedGoogle Scholar
  46. 46.
    Prieto-Alhambra D, Javaid MK, Servitja S, Arden NK, Martinez-Garcia M, Diez-Perez A, Albanell J, Tusquets I, Nogues X (2011) Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. Breast Cancer Res Treat 125(3):869–878. doi: 10.1007/s10549-010-1075-9 CrossRefPubMedGoogle Scholar
  47. 47.
    Garcia-Giralt N, Rodriguez-Sanz M, Prieto-Alhambra D, Servitja S, Torres-Del Pliego E, Balcells S, Albanell J, Grinberg D, Diez-Perez A, Tusquets I, Nogues X (2013) Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study. Breast Cancer Res Treat 140(2):385–395. doi: 10.1007/s10549-013-2638-3 CrossRefPubMedGoogle Scholar
  48. 48.
    Galantino ML, Desai K, Greene L, Demichele A, Stricker CT, Mao JJ (2012) Impact of yoga on functional outcomes in breast cancer survivors with aromatase inhibitor-associated arthralgias. Integr Cancer Ther 11(4):313–320. doi: 10.1177/1534735411413270 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Janine M. Lombard
    • 1
    • 2
    • 3
    Email author
  • Nicholas Zdenkowski
    • 1
    • 2
    • 3
  • Kathy Wells
    • 4
  • Corinna Beckmore
    • 3
  • Linda Reaby
    • 3
  • John F. Forbes
    • 1
    • 2
    • 3
  • Jacquie Chirgwin
    • 2
    • 3
    • 5
  1. 1.Calvary Mater NewcastleNewcastleAustralia
  2. 2.University of NewcastleNewcastleAustralia
  3. 3.Australia and New Zealand Breast Cancer Trials GroupNewcastleAustralia
  4. 4.Breast Cancer Network AustraliaNewcastleAustralia
  5. 5.Monash UniversityNewcastleAustralia

Personalised recommendations